> 首页 > 产品 > 一抗 > 精选抗体 > Anti-PAD4 Reference Antibody (BMS patent anti-PAD4)

Anti-PAD4 Reference Antibody (BMS patent anti-PAD4)

Anti-PAD4 Reference Antibody (BMS patent anti-PAD4) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-PAD4 Reference Antibody (BMS patent anti-PAD4) is 98.6%, determined by SEC-HPLC.
Immobilized PAD4-His , It’s target at 2 µg/mL can bind BMS patent anti-PAD4, EC50= 0.008549 µg/mL.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9UM07
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	74079 Da

Additional Information
Target/Specificity	PAD4
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	PADI4 {ECO:0000303\|PubMed:12833157, ECO:0000312\|HGNC:HGNC:18368}
Function	Catalyzes the citrullination/deimination of arginine residues of proteins such as histones, thereby playing a key role in histone code and regulation of stem cell maintenance (PubMed:15339660, PubMed:15345777, PubMed:16567635, PubMed:19153223, PubMed:21245532, PubMed:25622091). Citrullinates histone H1 at 'Arg-54' (to form H1R54ci), histone H3 at 'Arg-2', 'Arg-8', 'Arg-17' and/or 'Arg-26' (to form H3R2ci, H3R8ci, H3R17ci, H3R26ci, respectively) and histone H4 at 'Arg-3' (to form H4R3ci) (PubMed:15339660, PubMed:15345777, PubMed:16567635, PubMed:21245532). Acts as a key regulator of stem cell maintenance by mediating citrullination of histone H1: citrullination of 'Arg-54' of histone H1 (H1R54ci) results in H1 displacement from chromatin and global chromatin decondensation, thereby promoting pluripotency and stem cell maintenance (PubMed:15339660, PubMed:15345777, PubMed:16567635, PubMed:21245532). Promotes profound chromatin decondensation during the innate immune response to infection in neutrophils by mediating formation of H1R54ci (PubMed:18209087). Citrullination of histone H3 prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription (PubMed:15345777). Involved for the formation of neutrophil extracellular traps (NETs) by mediating citrullination of histone H3 and initiating decondensation of chromatin and nuclear membrane rupture (PubMed:19153223, PubMed:25622091, PubMed:28574339, PubMed:32170015). NETs are mainly composed of DNA fibers and are released by neutrophils to trap pathogens during inflammation (PubMed:19153223). Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1 (PubMed:15731352).
Cellular Location	Cytoplasm. Nucleus. Cytoplasmic granule. Note=Cytoplasmic granules of eosinophils and neutrophils.
Tissue Location	Expressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes